CompletedNot Applicable

Impact of Vitamin D Supplementation on Cardiac Structure and Function

United States1,025 participantsStarted 2010-07-01

Plain-language summary

The VITamin D and OmegA-3 TriaL (VITAL; NCT 01169259) is a randomized clinical trial in 20,000 U.S. men and women investigating whether taking daily dietary supplements of vitamin D3 (2000 IU) or fish oil (1 gram of omega-3 fatty acids) reduces the risk of developing cancer, heart disease, and stroke in people who do not have a prior history of these illnesses. This ancillary study (VITAL-Echo) is being conducted among participants in VITAL and will examine whether vitamin D compared to placebo: (1) reduces left ventricular (LV) mass in elderly individuals as measured with 2-dimensional echocardiography and (2) improves LV systolic and diastolic function as measured with tissue Doppler echocardiography.

Who can participate

Age range50 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Participants in VITAL (NCT 01169259) who meet the following criteria are eligible to participate in this ancillary study: Inclusion: * Willingness to participate in ancillary study of VITAL to undergo cardiac echocardiography (baseline and at 3 years) and sign informed consent to participate in the ancillary study * Live in the greater Boston area (within 60 miles of MGH) Exclusion: * Have a pacemaker, prosthetic valve(s), surgical wires or other devices that could alter the echocardiographic image findings.

What they're measuring

Change in left ventricular (LV) mass

Timeframe: Baseline and 2 years

Trial details

NCT IDNCT01630213

SponsorMassachusetts General Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2016-04-11

View on ClinicalTrials.gov More Cardiovascular Disease trials